<DOC>
	<DOCNO>NCT02414425</DOCNO>
	<brief_summary>Fecal incontinence frequent pathology concern 10 % general population severely alter patient quality life . The cost urinary faecal incontinence estimate $ 16 billion year . Several treatment exist depend aetiology faecal incontinence : medical treatment , biofeedback sacral nerve stimulation . Nevertheless , treatment always effective ( 50-70 % success ) without side effect , particularly sacral nerve stimulation ( pain , infection , electrode displacement.. ) . The intravesical injection botulinum toxin use several year treatment urinary incontinence overactive bladder . Several randomized trial demonstrate efficacy injection patient neurological disorder overactive bladder , well idiopathic overactive bladder . The toxin injection detrusor muscle increase compliance bladder capacity delay initial appearance detrusor uninhibited contraction . Furthermore , botulinum toxin decrease urinary urgency . It maybe secondary reduction amplitude detrusor uninhibited contraction well direct effect toxin sensory pelvic nerve afferent . The botulinum toxin play role motor afferent well sensory function efferent nerve . The hypothesis demonstrate decrease active faecal incontinence and/or urgency episode improvement quality life , without major side effect , patient include study . Nevertheless , benefit toxin injection know temporary nerve re-growth . If obtain similar result fecal incontinence , would possible schedule one two injection year limit side-effects invasiveness rectal injection .</brief_summary>
	<brief_title>Effect Tolerance Botulinum A Toxin Rectal Injections Fecal Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Fecal Incontinence</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients least one episode active Fecal Incontinence /or urgency per week ; Patients Fecal Incontinence least 3 month ; Patients Fecal Incontinence refractory conventional treatment ( medical biofeedback ) ; Patients read information letter sign informed consent ; Patients medical insurance . Patients young 18 year old ; Pregnant breastfeed woman woman without effective contraception age procreate ; Exclusive passive Fecal Incontinence ; Fecal Incontinence secondary anorectal malformation , postsurgery , anorectal organic disease ( cancer , inflammatory bowel disease , postradiotherapy etc . ) , constipation , anal sphincter lesion could repair first step , rectal prolapse ( inclusion study possible Fecal Incontinence persist rectopexy , neurological disease rapid progress ( stable neurological status need least 6 month ) ; Patients guardianship . Known Hypersensibility botulinum toxin ; Neuromuscular junction pathology ( myasthenia , LambertEaton syndrome ) ; Anesthesia perform less 1 month previously ; Association antibiotic Neurological pathology polyradiculoneuropathy ; Dysphagia , pneumopathy secondary dysphagia ; Botulinum toxin injection 3 month begin study ; Known Hypersensitivity albumin ; History inhalation pneumopathy . Rectoscopy impossible ( anal stenosis example ) ; Anticoagulant antiplatelet drug hemostasis disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Fecal Incontinence</keyword>
	<keyword>Botulinum Toxin A</keyword>
	<keyword>Rectal injection</keyword>
</DOC>